Skip to main content
OpenTrials
Completed

NCT Number: NCT01424150

REstrictive Versus LIbEral Fluid Therapy in Major Abdominal Surgery: RELIEF Study

The optimal fluid regimen, haemodynamic (or other) targets and fluid choice (colloid or crystalloid) for patients undergoing major surgery are based on rationales that are not supported by strong evidence. Practices vary substantially, guidelines are vague, small trials and meta-analyses are contradictory. The strongest and most consistent evidence, and biological plausibility because of tissue edema, supports a restrictive fluid strategy. But other evidence supports goal-directed therapy, requiring additional IV fluid. There is no good evidence that use and choice of colloids improves outcome. RELIEF will study the effects of fluid restriction, and the possible effect-modification of goal-directed therapy and colloids. The first will be randomly assigned; the latter will be measured covariates dictated by local practices and beliefs.

Study Hypotheses A restrictive fluid regimen for adults undergoing major abdominal surgery leads to reduced complications and improved disability-free survival when compared with a liberal fluid regimen.

Secondary hypothesis: The effects of fluid restriction are similar whether or not goal-directed therapy is used (assessed as a statistical test of interaction). A restrictive fluid regimen will reduce a composite of 30-day septic complications and mortality.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Alfred Hospital

Melbourne, Victoria, 3004, Australia

About this study

The investigators have completed a pilot study of 82 subjects to test the feasibility of the trial (2011), and are currently doing a cost-effectiveness substudy (2012-13)

  • AIM OF THE TRIAL To investigate the effectiveness of fluid restriction (vs. liberal), and the possible effect-modification of goal-directed therapy (eg. oesophageal Doppler, Flotrac®). The first will be randomly assigned; the latter will be measured covariates according to local practices and beliefs.

The optimal fluid regimen and haemodynamic (or other) targets for patients undergoing major surgery are based on rationales that are not supported by strong evidence. Practices vary substantially; guidelines are vague, small trials and meta-analyses are contradictory. The strongest and most consistent evidence, and biological plausability regarding tissue oedema, supports a restrictive fluid strategy. There is less (and more contradictory) evidence supporting goal-directed therapy using a flow-directed device and/or dopexamine, and use and choice of colloids. A large, definitive clinical trial evaluating perioperative fluid replacement in major surgery is required.

Study Hypotheses A restrictive fluid regimen for adults undergoing major abdominal surgery leads to reduced complications and improved disability-free survival when compared with a liberal fluid regimen.

Secondary hypotheses: The effects of fluid restriction are similar whether or not goal-directed therapy is used (assessed as a statistical test of interaction). A restrictive fluid regimen will reduce a composite of 30-day septic complications and mortality.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults (≥18 years) undergoing elective major surgery and providing informed consent
  • All types of open or lap-assisted abdominal or pelvic surgery with an expected duration of at least 2 hours, and an expected hospital stay of at least 3 days (for example, oesophagectomy, gastrectomy, pancreatectomy, colectomy, aortic or aorto-femoral vascular surgery, nephrectomy, cystectomy, open prostatectomy, radical hysterectomy, and abdominal incisional hernia repair)
  • At increased risk of postoperative complications, defined as at least one of the following criteria:
  • age ≥70 years
  • known or documented history of coronary artery disease
  • known or documented history of heart failure
  • diabetes currently treated with an oral hypoglycaemic agent and/or insulin
  • preoperative serum creatinine >200 µmol/L (>2.8 mg/dl)
  • morbid obesity (BMI ≥35 kg/m²)
  • preoperative serum albumin <30 g/L
  • anaerobic threshold (if done) <12 mL/kg/min
  • or two or more of the following risk factors:
  • ASA 3 or 4
  • chronic respiratory disease
  • obesity (BMI 30-35 kg/m²)
  • aortic or peripheral vascular disease
  • preoperative haemoglobin <100 g/L
  • preoperative serum creatinine 150-199 µmol/L (>1.7 mg/dl)
  • anaerobic threshold (if done) 12-14 mL/kg/min

Exclusion criteria

  • Urgent or time-critical surgery
  • ASA physical status 5 - such patients are not expected to survive with or without surgery, and their underlying illness is expected to have an overwhelming effect on outcome (irrespective of fluid therapy)
  • Chronic renal failure requiring dialysis
  • Pulmonary or cardiac surgery - different pathophysiology, and thoracic surgery typically have strict fluid restrictions
  • Liver resection - most units have strict fluid/CVP limits in place and won't allow randomisation
  • Minor or intermediate surgery, such as laparoscopic cholecystectomy, transurethral resection of the prostate, inguinal hernia repair, splenectomy, closure of colostomy - each of these are typically "minor" surgery with minimal IV fluid requirements, generally low rates of complications and mostly very good survival.

Treatment and study plan

Liberal fluid therapy

Other

Liberal protocol group is designed to provide approximately 6.0L per day.

Restrictive Fluid Therapy

Other

Restrictive protocol group is designed to provide less than 2.0 L water and 120 mmol sodium per day.

Primary outcomes

  1. Disability-free Survival

    Time frame: 1 year postoperative

    Disability-free survival up to 1 year: survival and freedom from disability. The latter is defined as a persistent (≥6 months) reduction in health status as measured by a 12-item version (12-60 points) of World Health Organisation Disability Assessment Schedule score (WHODAS) of 24 points, reflecting a disability level of at least 25% and being the threshold point between "disabled" and "not disabled" as per WHO guidelines. Disability will be assessed by the participant, but if unable then we will use the proxy's report. The date of onset of new disability will be recorded. Further details are provided in the Procedures Manual and the Statistical Analysis Plan.

Secondary outcomes

  1. Death

    Time frame: 90 days, then up to 12 months after surgery

    deceased within 12 months

  2. Composite Septic Outcome or Death

    Time frame: 30 days postoperative

    composite of 1 or more of:sepsis, surgical site infection, anastomotic leak, death and pneumonia

  3. Sepsis

    Time frame: 30 days postoperative

    using Centers for Disease Control and Prevention (CDC) with National Healthcare Safety Network (NHSN) criteria, two or more features of the systematic inflammatory response syndrome (SIRS) plus evidence of a source or site of infection (can be positive blood culture or purulence from any site)

  4. Surgical Site Infection

    Time frame: 30 days postoperative

    using CDC criteria (http://www.cdc.gov/nhsn/PDFs/pscManual/9pscSSIcurrent.pdf):

  5. Pneumonia

    Time frame: 30 Days postoperative

    The presence of new and/or progressive pulmonary infiltrates on chest radiograph plus two or more of the following:

    • Fever ≥ 38.5°C or postoperative hypothermia <36°C
    • Leukocytosis ≥ 12,000 WBC/mm3 or leukopenia < 4,000 WBC/mm3
    • Purulent sputum and/or
    • New onset or worsening cough or dyspnoea.
  6. Acute Kidney Injury

    Time frame: 30 days postoperative

    according to The Kidney Disease: Improving Global Outcomes (KDIGO) group criteria, but not urine output - for Stage 2 or worse AKI defined as at least 2-fold increase in creatinine, or estimated GFR decrease >50%.(73) We also plan to report renal replacement therapy up to 90 days after surgery. Because a restrictive IV fluid regimen may artificially elevate serum creatinine due to a smaller dilutional effect from less IV fluids, we therefore calculated adjusted creatinine by first estimating the volume of distribution for creatinine as equal to total body water (assumed to be 60% of body weight, expressed in mL).

  7. Pulmonary Oedema

    Time frame: 30 days postoperative

    respiratory distress or impaired oxygenation AND radiological evidence of pulmonary oedema

  8. Total Duration of Time Spend in the ICU or HDU (in Days)

    Time frame: 30 day postoperative

    including initial ICU admission and readmission times up to 30 days post operatively

  9. Hospital Stay

    Time frame: 30 days postoperative

    from the start (date, time) of surgery until actual hospital discharge

  10. Quality of Recovery

    Time frame: days 3

    15-item Quality of Recovery Score. The score is a patient reported outcome measure to score the individuals recovery following anaesthesia and surgery. Minimum value is 0 and maximum value is 150. The score of 150 is good. The higher the score the better

  11. Anastomotic Leak

    Time frame: 30 days postoperative

    A defect of the intestinal wall at the anastomotic site (including suture and staple lines of neorectal reservoirs) leading to a communication between the intra- an extra luminal compartments.

  12. C-reactive Protein

    Time frame: Day 3 postoperative

    plasma C-reactive protein (CRP, using site-specific assay) concentration on Day 3

  13. mmol/L

    Time frame: 24 hours post surgery

    peak serum lactate within 24 hours of surgery

  14. Total ICU Stay and Unplanned ICU Admission to ICU

    Time frame: 30 days postoperative

    additive, including initial ICU admission and readmission times up to Day 30

Other outcomes

  1. Preplanned Substudies (for Mechanistic Understanding)

    Time frame: 5 years

    We plan several substudies (to be funded from other sources), each of which will have a separate protocol and authorship plan (using an expanded list of contributors). Additional blood tests and other investigations will be done at selected hospitals according to local interest and expertise.

    • Cost-effectiveness, to include hospital stay and complications as we have done previously
    • Hyperchloraemic acidosis (to measure strong ion difference, Cl-, lactate, albumin …)
    • Pulmonary oedema and acute lung injury (to measure FiO2/PaO2 ratio, CT/CXR-confirmed atelectasis …)
    • Perioperative oliguria and acute kidney injury 5. Obesity and perioperative risk 6. BNP and risk prediction 7. Goal directed therapy - decision analysis 8. Perioperative diabetes and HbA1C 9. CKD follow-up

Sponsors and collaborators

Lead sponsor

Bayside Health

Other Gov

Collaborators

  • National Health and Medical Research Council, Australia

Registry information

Official study title

Restrictive Versus Liberal Fluid Therapy in Major Abdominal Surgery

Acronym: RELIEF

Important dates

Study start
2013
Primary completion
2017
Study completion
2017
First posted
Aug 26, 2011
Registry last updated
Jan 20, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.